Indicators on BCAT-IN-4 You Should Know
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important trial aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis s